LifeCycle sells North American royalties for Fenoglide

08/21/2008 | Reuters

LifeCycle Pharma, a Danish biotech company, has sold the North American royalty stream from its drug Fenoglide to Cowen Healthcare Royalty Partners in a deal worth as much as $105 million. Fenoglide, a cholesterol-lowering treatment, entered the U.S. market this year through Sciele Pharma.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA